The Carlat Psychiatry Podcast podcast

60 Sec Psych: Long-Term Treatment Response in Pediatric OCD

0:00
6:32
Spol 15 sekunder tilbage
Spol 15 sekunder frem

In 2004, the well-known pediatric OCD treatment study also known as POTS study revealed that CBT and sertraline had comparable benefits over 12 weeks of treatment for children with OCD. Yet this study left us with a few unanswered questions. For instance, for those who don't respond to initial CBT therapy, should we continue CBT or switch to an SSRI like sertraline.

CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.

Published On: 12/2/2021

Duration: 6 minutes, 32 seconds

Referenced Article: “Long-Term Treatment Response in Pediatric OCD,” The Carlat Child Psychiatry Report, March 2021

Joshua Feder, MD, has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Got feedback? Take the podcast survey.

Flere episoder fra "The Carlat Psychiatry Podcast"

  • The Carlat Psychiatry Podcast podcast

    Countertransference Hate and the Suicidal Patient

    9:16

    Psychoanalyst Dan Buie describes hateful reactions that are common when working with suicidal patients and how to manage these intense emotionsCME: Take the CME Post-Test for this episodePublished On: 01/10/2022Duration:  9 minutes, 16 secondsChris Aiken, MD, has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    Unusual Medication Effects from 2021

    16:00

    In 2021 we uncovered some paradoxical effects of medications, including meds that can both cause and treat OCD (antipsychotics), depression (benzodiazepines and antidepressants), and cognitive problems (stimulants and anti-dementia medications).CME: Take the CME Post-Test for this episodePublished On: 01/03/2022Duration: 16 minutes, 0 secondsReferenced Articles: “Stimulants and Creativity,”The Carlat Psychiatry Report, February 2021“Brexpiprazole Ineffective in Mania,” The Carlat Psychiatry Report, October 2021“The Schizophrenia-OCD Overlap,” The Carlat Psychiatry Report, October 2021Chris Aiken, MD, and Kellie Newsome, PMHNP, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    Gå ikke glip af nogen episoder af The Carlat Psychiatry Podcast - abonnér på podcasten med gratisapp GetPodcast.

    iOS buttonAndroid button
  • The Carlat Psychiatry Podcast podcast

    Better Billing, Better Care

    24:16

    DHHS recently unveiled the first major overhaul of its documentation guidelines for the E&M codes often used in outpatient psychiatry. We show you how to make those rules work for your patients.CME: Take the CME Post-Test for this episodePublished On: 12/27/2021Duration: 24 minutes, 16 secondsChris Aiken, MD, and Kellie Newsome, PMHNP, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.Got feedback? Take the podcast survey.
  • The Carlat Psychiatry Podcast podcast

    A New Way to Diagnose Bipolar

    16:06

    Gordon Parker suggests changes to the DSM-5 criteria for bipolar disorder, and unveils a new screening instrument that aims to separate hypomania from normal happiness.CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/20/2021Duration: 16 minutes, 07 secondsReferenced Article: “How to Diagnose Bipolar Disorder,” The Carlat Psychiatry Report, November/December 2021Chris Aiken, MD, Kellie Newsome, PMHNP, Gordon Parker, MD, PhD, DSc, and have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    Reading Research: Details Matter

    17:41

    You will hear about and read research your entire career. Headlines report on positive treatment results, and families come in asking about them. So how should we evaluate research, and what makes a study good or flawed?CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/17/2021Duration: 17 minutes, 41 secondsReferences: Database for reporting adverse eventsJoshua Feder, MD, and Mara Goverman, LCSW, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    How to Combat Tardive Dyskinesia with VMAT2 Inhibitors

    11:24

    For years, we have dreaded seeing our patients develop antipsychotic-induced tardive dyskinesia because there was little we could do about these symptoms. Thankfully, we now have new treatments that produce noticeable improvements in tardive dyskinesia. CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/15/2021Duration: 11 minutes, 23 secondsReferenced Article: “Finally, Effective Treatments for Tardive Dyskinesia,” The Carlat Hospital Psychiatry Report, April/May/June 2021Victoria Hendrick, MD, and Zachary Davis, BS, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    How to Prevent Cognitive Decline

    21:12

    Peter Whitehouse on how to prevent dementia and the limits of pharmacotherapy for cognitive decline. And the word of the day: Ultradian cycling.CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/13/2021Duration: 21 minutes, 12 secondsReferenced Article: “In the News: Aducanumab (Aduhelm),” The Carlat Psychiatry Report, November/December 2021Chris Aiken, MD, Kellie Newsome, PMHNP, and Peter J. Whitehouse, MD, PhD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    How to Manage Substance Use Disorder in Pregnancy

    18:03

    Pregnant patients with substance use disorder want to do what’s right for their pregnancy, and as clinicians, we need to be supportive and acknowledge our patients courage and vulnerability to seek help. But, what are the best treatments for the various substance use disorders in pregnant women, and which substances have the highest potential for producing negative pregnancy outcomes? CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/10/2021Duration: 18 minutes, 2 secondsReferenced Article: “The Pregnant Patient With Substance Use Disorder,” The Carlat Addiction Treatment Report, July/August 2021Noah Capurso, MD, MHS, and Ariadna Forray, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    A Child Psychiatry Research Update Extravaganza - Part 2

    14:35

    From melatonin for sleep-onset insomnia to electroconvulsive therapy for severe adolescent mood disorder to steroid-induced psychosis to the risk of stimulant-induced psychosis in youth with ADHD, and MORE! In this two-part series, Mara and Dr. Feder will tackle various research topics in the field of child psychiatry. CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/9/2021Duration: 14 minutes, 35 secondsReferenced Articles: “Risk of Psychosis With Stimulants in ADHD Patients,” The Carlat Child Psychiatry Report, May/June/July/August 2021“Vitamin D for ADHD?,” The Carlat Child Psychiatry Report, October/November/December 2020“Efficacy and Safety of SSRIs and SNRIs for Child and Adolescent Psychiatric Disorders,” The Carlat Child Psychiatry Report, January/February 2018Joshua Feder, MD, and Mara Goverman, LCSW, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
  • The Carlat Psychiatry Podcast podcast

    Managing Metabolic Side Effects in Schizophrenia

    16:42

    Individuals with schizophrenia are at high risk of obesity, elevated lipids, increased insulin resistance, diabetes, and cardiovascular disease. On average, people with schizophrenia die 20–25 years sooner than those without schizophrenia. How can we spot metabolic side effects early in our patients, and what should we be looking for exactly? CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.Published On: 12/8/2021Duration: 16 minutes, 42 secondsReferenced Article: “Weight Gain and Metabolic Side Effects,” The Carlat Hospital Psychiatry Report, July/August/September 2021Victoria Hendrick, MD, and Stephen Marder, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Få adgang til hele det store podcastunivers med gratisappen GetPodcast.

Abonnér på dine favoritpodcasts, lyt til episoder offline, og få spændende anbefalinger.

iOS buttonAndroid button
© radio.de GmbH 2022radio.net logo